Looks like you clickedhttps://www.prnewswire.com/news-releases/catapult-therapeutics-receives-fda-clearance-of-investigational-new-drug-ind-application-for-cap-100-an-innovative-first-in-class-humanized-anti-ccr7-antibody-301223908.html
If you do not want to visit that page, you can close this browser tab.
